Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg High Yield Bond ETF vs TransMedics Group Inc — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $95.74, while TransMedics Group Inc trades at $70.87 (market cap $2.57B). The key difference: State Street SPDR Bloomberg High Yield Bond ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| JNK | TMDX | |
|---|---|---|
Sector | Fixed Income | Technology |
52-Week High | $98.19 | $150.42 |
52-Week Low | $94.66 | $61.99 |
Market Cap | — | $2.57B |
Enterprise Value | — | $2.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JNK trades at $95.95, down 0.03% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF maintains consistent dividend payments, with recent payouts of $0.52-$0.53. News highlights strong inflows into bond ETFs amid rising yields and Federal Reserve uncertainty, though some analysts caution on high-yield exposure.
Outlook is cautious due to bearish technicals and mixed sentiment; opportunities exist for income-seeking investors via dividends, but risks include potential Fed rate hikes and inflation pressures that could pressure high-yield bonds. Investor focus remains on macroeconomic cues.
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
